Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis.
Journal: Leukemia & lymphoma
Published: July 08, 2024
Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials.
Journal: Leukemia & lymphoma
Published: May 24, 2024
Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma.
Journal: Leukemia & lymphoma
Published: October 16, 2023
Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients.
Journal: Advances in therapy
Published: July 11, 2023
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
Journal: British journal of haematology
Published: June 14, 2022
Calpain-1 regulation of matrix metalloproteinase 2 activity in vascular smooth muscle cells facilitates age-associated aortic wall calcification and fibrosis.
Journal: Hypertension (Dallas, Tex. : 1979)
Published: September 26, 2012
Chronic matrix metalloproteinase inhibition retards age-associated arterial proinflammation and increase in blood pressure.
Journal: Hypertension (Dallas, Tex. : 1979)
Published: June 13, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026